**Core Concept**
The question is testing the underlying principle of using xylometazoline nasal drops before nasotracheal intubation, which involves **vasoconstriction** and **anesthesia** of the nasal mucosa. Xylometazoline is an **alpha-2 adrenergic receptor agonist** that causes vasoconstriction, reducing nasal congestion and bleeding.

**Why the Correct Answer is Right**
Xylometazoline nasal drops are given before nasotracheal intubation to reduce bleeding and congestion in the nasal passages, making the intubation process easier and safer. By causing **vasoconstriction**, xylometazoline decreases the risk of bleeding and trauma to the nasal mucosa during intubation.

**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because while xylometazoline does have some anesthetic properties, its primary purpose in this context is vasoconstriction.
**Option B:** Incorrect as this is not the primary purpose of xylometazoline in nasotracheal intubation.
**Option C:** Incorrect because, although xylometazoline can help with anesthesia, this is not its main use in this scenario.
**Option D:** Incorrect as this option is not provided.

**Clinical Pearl / High-Yield Fact**
A key point to remember is that xylometazoline should be used with caution in patients with **hypertension** and **thyrotoxicosis** due to its potential to exacerbate these conditions.

**Correct Answer:** D. To reduce bleeding and congestion during nasotracheal intubation.